AR121314A1 - ANTI-CD137 ANTIGEN-BINDING MOLECULES FOR ADMINISTRATION IN CANCER TREATMENT - Google Patents
ANTI-CD137 ANTIGEN-BINDING MOLECULES FOR ADMINISTRATION IN CANCER TREATMENTInfo
- Publication number
- AR121314A1 AR121314A1 ARP210100353A ARP210100353A AR121314A1 AR 121314 A1 AR121314 A1 AR 121314A1 AR P210100353 A ARP210100353 A AR P210100353A AR P210100353 A ARP210100353 A AR P210100353A AR 121314 A1 AR121314 A1 AR 121314A1
- Authority
- AR
- Argentina
- Prior art keywords
- anticancer agents
- combination treatments
- activity
- tissues
- antigen
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un objetivo de la presente divulgación es proporcionar: agentes anticancerígenos que tienen un efecto activador de la célula inmunitaria, una actividad citotóxica o una actividad antineoplásica, pero que tienen poco efecto en los tejidos no tumorales, tales como tejidos normales, y que tienen pocos efectos secundarios; tratamientos combinados que usan esos agentes anticancerígenos y otros agentes anticancerígenos; y combinaciones farmacéuticas para usar en esos tratamientos combinados. Se proporcionan agentes anticancerígenos que se espera aplicar a varios tipos de cánceres, que tiene un efecto activador de las células inmunitarias, una actividad citotóxica o una actividad antineoplásica, mientras que tienen poco efecto en los tejidos no tumorales, tales como tejidos normales, y que tienen pocos efectos secundarios y utilizan como un ingrediente activo una molécula de unión a antígeno anti-CD137 de la presente divulgación, cuya actividad de unión a CD137 cambia dependiendo de varias sustancias (por ejemplo, compuestos de bajo peso molecular) en tejidos objetivo. También se proporcionan tratamientos combinados que utilizan los agentes anticancerígenos y otros agentes anticancerígenos, y las composiciones farmacéuticas para usar en esos tratamientos combinados.An object of the present disclosure is to provide: anticancer agents that have an immune cell activating effect, a cytotoxic activity, or an antineoplastic activity, but have little effect on non-tumor tissues, such as normal tissues, and have little effect secondaries; combination treatments using those anticancer agents and other anticancer agents; and pharmaceutical combinations for use in those combination treatments. Anticancer agents which are expected to apply to various types of cancers, which have an activating effect on immune cells, a cytotoxic activity or an antineoplastic activity, while having little effect on non-tumor tissues such as normal tissues, and which they have few side effects and use as an active ingredient an anti-CD137 antigen-binding molecule of the present disclosure, whose CD137-binding activity changes depending on various substances (eg, low molecular weight compounds) in target tissues. Combination treatments utilizing the anticancer agents and other anticancer agents, and pharmaceutical compositions for use in such combination treatments, are also provided.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020021275 | 2020-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121314A1 true AR121314A1 (en) | 2022-05-11 |
Family
ID=82401434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100353A AR121314A1 (en) | 2020-02-12 | 2021-02-11 | ANTI-CD137 ANTIGEN-BINDING MOLECULES FOR ADMINISTRATION IN CANCER TREATMENT |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR121314A1 (en) |
-
2021
- 2021-02-11 AR ARP210100353A patent/AR121314A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002150A1 (en) | Anti-cd137 antigen-binding molecules for delivery in cancer treatment | |
| ECSP14012676A (en) | CARBAMATE COMPOUNDS AND THE PREPARATION AND USE OF THEM | |
| DOP2019000294A (en) | ANTIMITOSCINAS: SPECIFIC INHIBITORS OF MITOCHONDRIAL BIOGENESIS TO ERADICATE CANCER STEM CELLS | |
| BR112018070580A2 (en) | methods and compositions for t cell therapy | |
| UY37168A (en) | PROPHARMS OF ACTIVE CYTOTOX PRINCIPLES WITH ENZYMATICALLY SCINDIBLE GROUPS | |
| CL2022001752A1 (en) | Pyridazinyl-thiazolecarboxamide compound | |
| Catanzaro et al. | Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression | |
| CO2023008271A2 (en) | Heteroarylcarboxamide compound | |
| BR112014027834A2 (en) | lipid nanoparticle compositions for antisense oligonucleotide delivery | |
| CU20120176A7 (en) | IMMUNOSUPPRESSION MODULATING COMPOUNDS CAPABLE OF INHIBITING THE PROGRAMMED CELLULAR DEATH SIGNALING PATH 1 | |
| Gándara et al. | The natural flavonoid silybin improves the response to Photodynamic Therapy of bladder cancer cells | |
| CU20100216A7 (en) | POLYPEPTIDES DERIVED FROM IL-2 WITH AGONISTIC ACTIVITY AND HIGHER EFFECTIVENESS FOR CANCER THERAPY AND CHRONIC INFECTIONS | |
| CO6300964A2 (en) | A PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN ANTIGLIPICAN ANTIBODY 3 | |
| GT201200069A (en) | VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS | |
| BR112015006828A8 (en) | compound, or a pharmaceutically acceptable salt thereof; pharmaceutical composition; use of the compound; and method for modulating the activity of an ire1 protein | |
| BR112017027985A2 (en) | therapeutic peptides and methods of use thereof | |
| AR114550A1 (en) | ANTI-CD137 ANTIGEN BINDING MOLECULES AND THEIR USES | |
| CO2022015305A2 (en) | Multispecific antigen-binding molecules targeting delta-like ligand 3 (dll3) and their uses | |
| RU2018107930A (en) | TLR4 AGONISTS, THEIR COMPOSITIONS AND USE FOR TREATMENT OF CANCER | |
| JP2016027036A (en) | Composition for external application, cosmetics, percutaneous absorption promoting composition, method for improving percutaneous absorbency of active ingredient in composition for external application, percutaneously-administered medicine, and composition for eye drops | |
| UY39420A (en) | LIPID CONJUGATES FOR THE TRANSPORT OF THERAPEUTIC AGENTS | |
| Ahmad Ganai et al. | Plant derived inhibitor Sulforaphane in combinatorial therapy against therapeutically challenging Pancreatic Cancer | |
| BR112019007863A2 (en) | innovative naphthyridinone derivatives and their use in the treatment of arrhythmia | |
| AR121314A1 (en) | ANTI-CD137 ANTIGEN-BINDING MOLECULES FOR ADMINISTRATION IN CANCER TREATMENT | |
| MX2023005371A (en) | Ρî¡î`rî³ modulators and methods of use. |